The earnings call highlighted substantial progress in the deployment and expansion of Nanox.ARC, significant growth in AI solutions, and record revenue from the USARAD business. However, challenges such as increased gross loss and ongoing regulatory delays were noted. The company remains optimistic about future growth and milestones.

Company Guidance

During the third quarter of 2024, Nanox provided detailed guidance on its strategic initiatives and financial performance. The company reported a GAAP net loss of $13.6 million, reduced from $21.4 million in the previous year, and achieved revenues of $3.0 million. They highlighted the successful deployment of 47 Nanox.ARC units across 7 U.S. states and plans to expand their sales and service teams to 30-40 personnel by the end of 2025. Additionally, Nanox is pursuing regulatory clearances with the U.S. FDA and EU's CE Mark to broaden their market reach. Their teleradiology services reached a quarterly record with $2.6 million in revenues, while AI solutions generated $0.4 million, signaling continued growth in these sectors. The company also emphasized its focus on innovation and strategic partnerships, including agreements with Oxford University Hospitals and other institutions, to drive significant shareholder value.

Expansion and Deployment of Nanox.ARC

Nanox deployed 47 units of its Nanox.ARC technology, with expansion across 7 states in the U.S. and strategic plans to double the pipeline and sales efforts.

Significant Growth in AI Solutions

Nanox AI secured new deals, including Oxford University Hospitals and received recognition in Time's Best Inventions of 2024 List. Revenue from AI solutions increased to $0.4 million from $0.1 million in the previous period.

Record Revenue from USARAD Business

The USARAD division generated a record $2.6 million in revenue for the quarter, showing continued growth and contribution to overall business lines.

Regulatory and Clinical Progress

Progress in regulatory efforts with the FDA and European Union, with ongoing trials in multiple locations such as Beilinson Hospital and Ghana.

---

Nano-X Imaging (NNOX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NNOX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 09, 2020	2020 (Q3)	- / -0.29	-0.07	-314.29% (-0.22)	―	―
Mar 02, 2021	2020 (Q4)	- / -0.18	-0.416	56.73% (+0.24)	―	―
May 11, 2021	2021 (Q1)	-0.23 / -0.15	-0.162	7.41% (+0.01)	―	―
Aug 10, 2021	2021 (Q2)	-0.26 / -0.28	-0.24	-16.67% (-0.04)	―	―
Nov 17, 2021	2021 (Q3)	-0.28 / -0.28	-0.29	3.45% (<+0.01)	―	―
Mar 31, 2022	2021 (Q4)	-0.26 / -0.41	-0.15	-173.33% (-0.26)	―	―
May 19, 2022	2022 (Q1)	- / -	-0.15	―	―	―
Aug 16, 2022	2022 (Q2)	-0.25 / -0.38	-0.28	-35.71% (-0.10)	―	―
Nov 10, 2022	2022 (Q3)	-0.42 / -0.37	-0.28	-32.14% (-0.09)	―
Mar 09, 2023	2022 (Q4)	-0.43 / -0.86	-0.437	-96.80% (-0.42)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

NNOX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 21, 2024	$5.89	$6.16	+4.58%
Aug 20, 2024	$7.24	$7.13	-1.52%
May 28, 2024	$8.43	$8.49	+0.71%
Apr 01, 2024	$9.77	$10.33	+5.73%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---